ArticleBlood advances2018
Genetic heterogeneity of cytogenetically normal AML with mutations of
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 64 citations in OpenAlex.
- Trial
- [Prognostic significance of CEBPA gene mutations in acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML.Blood cancer journal · 2025Article
- CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.International journal of hematology · 2024Review
- Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia.Annals of hematology · 2024Article
- Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia.Cancers · 2024Article
- Article
- Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations.Blood cancer journal · 2024Article
- TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.Nature communications · 2023Article
- CSF3R T618I Collaborates With RUNX1-RUNX1T1 to Expand Hematopoietic Progenitors and Sensitizes to GLI Inhibition.HemaSphere · 2023Article
- Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors.Cancers · 2023Review
- Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia.Cancer research and treatment · 2023Article
- Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Leukemia · 2023Article
- Estrogens revert neutrophil hyperplasia by inhibiting Hif1α-cMyb pathway in zebrafish myelodysplastic syndromes models.Cell death discovery · 2022Article
- Systematic analysis of prognostic significance, functional enrichment and immune implication of STK10 in acute myeloid leukemia.BMC medical genomics · 2022Article
- ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.Blood advances · 2022Article
- DissectingCancers · 2022Review
- Acute Myeloid Leukemia-Related Proteins Modified by Ubiquitin and Ubiquitin-like Proteins.International journal of molecular sciences · 2022Review
- Acute Myeloid Leukemia WithFrontiers in oncology · 2022Review
- CEBPG promotes acute myeloid leukemia progression by enhancing EIF4EBP1.Cancer cell international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 2 countries.
Nikola P KonstandinLaboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany.
Friederike PastoreDepartment of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany.
Tobias HeroldLaboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany.ORCID 0000-0002-9615-9432
Annika DufourLaboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany.
Maja Rothenberg-ThurleyLaboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany.
Tanja HinrichsenCenter for Human Genetics and Laboratory Medicine, Martinsried, Germany.
Bianka KsienzykLaboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany.
Sebastian TschuriLaboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany.
Stephanie SchneiderLaboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany.
Eva HosterInstitute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany.ORCID 0000-0002-0749-1389
Wolfgang E BerdelDepartment of Medicine A-Hematology, Oncology and Pneumology, University of Münster, Münster, Germany.
Bernhard J WoermannDivision of Hematology, Oncology and Tumor Immunology, Department of Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Maria C SauerlandInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
Jan BraessDepartment of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany; and.
Stefan K BohlanderLeukaemia & Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand.ORCID 0000-0002-2202-9088
Hanns-Georg KleinCenter for Human Genetics and Laboratory Medicine, Martinsried, Germany.
Wolfgang HiddemannLaboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany.
Klaus H MetzelerLaboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany.ORCID 0000-0003-3920-7490
Karsten SpiekermannLaboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany.
German Cancer Research Center · DELudwig-Maximilians-Universität München · DEMedical Genetics Center · DEUniversity of Münster · DECharité - Universitätsmedizin Berlin · DEKrankenhaus Barmherzige Brüder · DEUniversity of Auckland · NZZimmer Biomet (Germany) · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biallelic mutations of the CCAAT/enhancer binding protein α (
Indexed as
AdolescentAdultAgedCCAAT-Enhancer-Binding Protein-alphaCCAAT-Enhancer-Binding ProteinsCytogeneticsFemaleGenetic HeterogeneityHumansMaleMiddle AgedMutationPrognosisYoung AdultCCAAT-Enhancer-Binding Protein-alphaCCAAT-Enhancer-Binding ProteinsCEBPA protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.